OncoMatch/Clinical Trials/NCT07117890
Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations
Is NCT07117890 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including sunvozertinib 300mg and sunvozertinib 200mg for non small cell lung cancer.
Treatment: sunvozertinib 300mg · sunvozertinib 200mg — This study is a single arm study to access the anti-tumor efficacy and safety of sunvozertinib in untreated advanced NSCLC patients with EGFR uncommon mutations.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR uncommon mutation (excluding 19del, L858R, T790M, Ex 20ins)
documented EGFR uncommon mutations from a local laoratory. at least one EGFR uncommon mutation (excluding EGFR 19del/l858r/T790m/Ex 20ins ) or compund mutations with EGFR uncommon mutations.
Prior therapy
Cannot have received: systemic anti-tumor therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07117890 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require EGFR?
Yes, EGFR uncommon mutation (excluding 19del, L858R, T790M, Ex 20ins) is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages